abstract：:We retrospectively studied 87 patients aged from 55 to 69 years old with acute myeloid leukemia (AML) who received decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin (DCAG) or standard dose chemotherapy as induction therapy. Patients receiving DCAG had a similar overall response rate (ORR) (p = ...

journal_title：Leukemia & lymphoma

authors： Huang J,Hong M,Zhu Y,Zhao H,Zhang X,Wu Y,Lian Y,Zhao X,Li J,Qian S

更新日期：2018-11-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLBCL) is a high-grade lymphoma that requires treatment. We retrospectively analyzed the impact of time from diagnosis-to-treatment (TDT) on progression-free survival (PFS) and overall survival (OS) in 581 R-CHOP-treated patients. TDT was defined as the interval between diagnostic biopsy...

journal_title：Leukemia & lymphoma

authors： Phipps C,Lee YS,Ying H,Nagarajan C,Grigoropoulos N,Chen Y,Tang T,Goh AZ,Ghosh A,Ng HJ,Gopalakrishnan S,Loh Y,Lim ST,Hwang W,Tan D,Goh YT

更新日期：2018-10-01 00:00:00

abstract：:Oncoproteins play a vital role in the pathogenesis of myeloid leukemia. Most targeted therapies for myeloid leukemia are small molecules or monoclonal antibodies that inhibit the activity of the oncoproteins. However, leukemia cells often develop resistance to these drugs through overexpression of the target protein a...

journal_title：Leukemia & lymphoma

authors： Lei H,Wang W,Wu Y

更新日期：2018-10-01 00:00:00

abstract：:Recurrent cytogenetic abnormalities have provided the backbone for prognosticating acute myeloid leukemia and predicting response to consolidative therapies for decades. However, more than 45% of acute myeloid leukemia patients have normal cytogenetics on both karyotype and fluorescence in situ hybridization at diagno...

journal_title：Leukemia & lymphoma

authors： McCurdy SR,Levis MJ

更新日期：2018-09-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is rare among children and adolescents. The early molecular response (EMR) is an important prognostic significance for adult CML patients. This study explored the impact of EMR on the prognosis in 40 children and adolescents with CML-CP treated with imatinib (IM). Our results showed that...

journal_title：Leukemia & lymphoma

authors： Shao H,Zeng Z,Cen J,Zhang J,Bai S,Wu C,Gong Y,Wang Y,Qiu H,Chen S,Pan J

更新日期：2018-09-01 00:00:00

abstract：:High-dose melphalan (HDM) followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard-of-care therapy for multiple myeloma (MM) even with the availability of proteasome inhibitors and immunomodulatory drugs. Gastrointestinal (GI) toxicity is the main cause of morbidity after HDM. Amifosti...

journal_title：Leukemia & lymphoma

authors： Malek E,Gupta V,Creger R,Caimi P,Vatsayan A,Covut F,Bashir Q,Champlin R,Delgado R,Rondon G,Cooper B,de Lima M,Lazarus HM,Qazilbash M

更新日期：2018-08-01 00:00:00

abstract：:This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In...

journal_title：Leukemia & lymphoma

authors： Ma J,Dunlap J,Paliga A,Traer E,Press R,Shen L,Fan G

更新日期：2018-08-01 00:00:00

abstract：:Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted immunotherapy which have induced remissions in some patients with chemotherapy refractory or relapsed (RR) hematologic malignancies. Hundreds of patients have now been treated worldwide with anti-CD19 CART cells, with complete response rates o...

journal_title：Leukemia & lymphoma

authors： Cummins KD,Gill S

更新日期：2018-07-01 00:00:00

abstract：:Ponatinib is a pan-tyrosine kinase inhibitor (TKI) with efficacy in multirefractory CML patients who have failed other TKIs. Despite excellent response rates, resistance or intolerance may develop. We conducted a retrospective review of the outcome of patients with chronic (CP) and accelerated (AP) phase CML refractor...

journal_title：Leukemia & lymphoma

authors： Boddu P,Shah AR,Borthakur G,Verstovsek S,Garcia-Manero G,Daver N,Kadia T,Ravandi F,Jain N,Alhuraiji A,Burger J,Kornblau S,Pierce S,Dellasala S,Jabbour E,Kantarjian H,Cortes J

更新日期：2018-06-01 00:00:00

abstract：:Infectious complications following treatment of acute myeloid leukemia (AML) are important causes of morbidity and mortality. The spectrum and complexity of these infections is reflected by the severe net state of immunosuppression of AML patients, that is dynamic and continuously changing, the polypharmacy, including...

journal_title：Leukemia & lymphoma

authors： Mulanovich V,Kontoyiannis DP

更新日期：2018-06-01 00:00:00

abstract：:INHBA (inhibin βA), a subunit of a ligand of the transforming growth factor-β superfamily, is known to play diverse roles in various solid tumors. However, its role in hematologic malignancies remains unexplored. Here, we investigated the function of INHBA in diffuse large B-cell lymphoma (DLBCL). Both mRNA and protei...

journal_title：Leukemia & lymphoma

authors： Jiang L,Si T,Yu M,Zeng X,Morse HC 3rd,Lu Y,Ouyang G,Zhou JX

更新日期：2018-05-01 00:00:00

abstract：:Matrix high-throughput screening (HTS) methods are increasingly employed to rapidly define potential therapeutic drug combinations. We used combination HTS to identify compounds showing synergistic anti-proliferative activity with ibrutinib, an irreversible, small-molecule inhibitor of Bruton's tyrosine kinase. The go...

journal_title：Leukemia & lymphoma

authors： Schaffer M,Chaturvedi S,Davis C,Aquino R,Stepanchick E,Versele M,Liu Y,Yang J,Lu R,Balasubramanian S

更新日期：2018-04-01 00:00:00

abstract：:The development of immune checkpoint inhibitors represents a major breakthrough in the field of cancer therapeutics. Pursuant to their success in melanoma and numerous solid tumor malignancies, these agents are being investigated in hematological malignancies including acute myelogenous leukemia (AML) and myelodysplas...

journal_title：Leukemia & lymphoma

authors： Boddu P,Kantarjian H,Garcia-Manero G,Allison J,Sharma P,Daver N

更新日期：2018-04-01 00:00:00

abstract：:Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains unclear. Romidepsin is a potent, class-I selective histone deacetyla...

journal_title：Leukemia & lymphoma

authors： Duvic M,Bates SE,Piekarz R,Eisch R,Kim YH,Lerner A,Robak T,Samtsov A,Becker JC,McCulloch W,Waksman J,Whittaker S

更新日期：2018-04-01 00:00:00

abstract：:This post-hoc subanalysis of the LYM-3002 phase 3 study assessed the efficacy and safety of substituting vincristine in rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHOP; n = 42) for bortezomib (VR-CAP; n = 38) in a subgroup of 80 mantle cell lymphoma (MCL) patients aged <60 years who did not receive ste...

journal_title：Leukemia & lymphoma

authors： Drach J,Huang H,Samoilova O,Belch A,Farber C,Bosly A,Novak J,Zaucha J,Dascalescu A,Bunworasate U,Masliak Z,Vilchevskaya K,Robak T,Pei L,Rooney B,van de Velde H,Cavalli F

更新日期：2018-04-01 00:00:00

abstract：:This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one week prior to Cycle 1 (C1) of ICE and during two weeks of C1-2 of ICE...

journal_title：Leukemia & lymphoma

authors： Hu B,Younes A,Westin JR,Turturro F,Claret L,Feng L,Fowler N,Neelapu S,Romaguera J,Hagemeister FB,Rodriguez MA,Samaniego F,Fayad LE,Copeland AR,Nastoupil LJ,Nieto Y,Fanale MA,Oki Y

更新日期：2018-04-01 00:00:00

abstract：:We investigated CD25 expression in older (≥60 years) patients with new acute myelogenous leukemia treated with decitabine and plerixafor. Patients resistant to therapy or survival ≤1 year had significantly higher percentages of CD25pos myeloid blasts in baseline bone marrow. CD25pos patients had an increased odds of r...

journal_title：Leukemia & lymphoma

authors： Allan JN,Roboz GJ,Askin G,Ritchie E,Scandura J,Christos P,Hassane DC,Guzman ML

更新日期：2018-04-01 00:00:00

abstract：:Existing prognostic tools for HIV + diffuse large B-cell lymphoma (DLBCL) fail to accurately predict patient outcomes. To develop a novel prognostic algorithm incorporating molecular tumor characteristics and HIV disease factors, we included 80 patients with HIV-related DLBCL diagnosed between 1996 and 2007. Immunohis...

journal_title：Leukemia & lymphoma

authors： Chao C,Silverberg MJ,Chen LH,Xu L,Martínez-Maza O,Abrams DI,Zha HD,Haque R,Said J

更新日期：2018-02-01 00:00:00

abstract：:Chemotherapy has long been integral to the treatment of chronic lymphocytic leukemia (CLL). Fludarabine/cyclophosphamide, chlorambucil and bendamustine are commonly used as a backbone, depending on the patient's age and general health. The advent of the anti-CD20 monoclonal antibodies, such as rituximab and obinutuzum...

journal_title：Leukemia & lymphoma

authors： Wendtner CM,Gregor M

更新日期：2018-02-01 00:00:00

abstract：:Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is ...

journal_title：Leukemia & lymphoma

authors： Bhatt VR,Gundabolu K,Koll T,Maness LJ

更新日期：2018-01-01 00:00:00

abstract：:To assess the efficacy of haploidentical hematopoietic stem cell transplantation (HSCT) in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH), we retrospectively analyzed 30 cases that presented at our institution. At the time of HSCT, 20 patients (66.7%) had achieved a resp...

journal_title：Leukemia & lymphoma

authors： Li Z,Wang Y,Wang J,Zhang J,Wang Z

更新日期：2018-01-01 00:00:00

abstract：:The management of AF represents a major challenge in patients with CLL, especially in elderly patients with multiple comorbidities who are representative of the majority of patients with CLL. This is especially complex in the case of ibrutinib. Many anticoagulants have potential for pharmacological interaction with ib...

journal_title：Leukemia & lymphoma

authors： Chai KL,Rowan G,Seymour JF,Burbury K,Carney D,Tam CS

更新日期：2017-12-01 00:00:00

abstract：:Progress in chronic lymphocytic leukemia (CLL) therapies has extended greatly the length and depth of remission, with the goal of treatment advancing towards a cure for some patients. Accordingly, clinical endpoints must evolve to capture these outcomes, and to provide faster access to novel therapies. Minimal residua...

journal_title：Leukemia & lymphoma

authors： Owen C,Christofides A,Johnson N,Lawrence T,MacDonald D,Ward C

更新日期：2017-12-01 00:00:00

abstract：:The decision to operate on hematology patients with abdominal emergencies can be difficult, as neutropenia and thrombocytopenia are common and the usual causes of abdominal pain are broad. We conducted a retrospective observational study including all hematology patients undergoing emergency abdominal surgery between ...

journal_title：Leukemia & lymphoma

authors： Mokart D,Penalver M,Chow-Chine L,Ewald J,Sannini A,Brun JP,Bisbal M,Lelong B,Delpero JR,Faucher M,Turrini O

更新日期：2017-10-01 00:00:00

abstract：:The detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in extragastric mucosa associated lymphoid tissue (MALT) lymphoma is under debate and the reason is not clear. Our aim was to investigate the metabolic behavior of extragastric MALT lymphoma and wheth...

journal_title：Leukemia & lymphoma

authors： Albano D,Bosio G,Giubbini R,Bertagna F

更新日期：2017-10-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders of the elderly that carry an increased risk of progression to acute myeloid leukemia (AML). Since small non-coding RNAs (sRNAs), including microRNA (miRNAs), act as regulators of cellular differentiation, we hypothesized that changes to sRNAs might be ...

journal_title：Leukemia & lymphoma

authors： Guo Y,Strickland SA,Mohan S,Li S,Bosompem A,Vickers KC,Zhao S,Sheng Q,Kim AS

更新日期：2017-09-01 00:00:00

abstract：:The approval of venetoclax, a 'BH3-mimetic' antagonist of the BCL-2 anti-apoptotic protein, for chronic lymphocytic leukemia represents a major milestone in translational apoptosis research. Venetoclax has already received 'breakthrough' designation for acute myeloid leukemia, and is being studied in many other tumor ...

journal_title：Leukemia & lymphoma

authors： Bose P,Gandhi V,Konopleva M

更新日期：2017-09-01 00:00:00

abstract：:Infection, relapse, and GVHD can complicate allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the effect of poor immune recovery on infection risk is well-established, there are limited data on the effect of immune reconstitution on relapse and survival, especially following T-cell depletion (TC...

journal_title：Leukemia & lymphoma

authors： Goldberg JD,Zheng J,Ratan R,Small TN,Lai KC,Boulad F,Castro-Malaspina H,Giralt SA,Jakubowski AA,Kernan NA,O'Reilly RJ,Papadopoulos EB,Young JW,van den Brink MR,Heller G,Perales MA

更新日期：2017-08-01 00:00:00

abstract：:Although BCR-ABL is the hallmark genetic abnormality of chronic myeloid leukemia (CML), secondary molecular events responsible for the evolution of the disease to blast crisis are yet to be deciphered. Taking into account the significant association of ecotropic viral integration site I (EVI1) in CML drug resistance, ...

journal_title：Leukemia & lymphoma

authors： Kuila N,Nayak KB,Halder A,Agatheeswaran S,Biswas G,Biswas S,Pattnayak NC,Chakraborty S

更新日期：2017-08-01 00:00:00

abstract：:We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having...

journal_title：Leukemia & lymphoma

authors： Shah GL,Landau H,Londono D,Devlin SM,Kosuri S,Lesokhin AM,Lendvai N,Hassoun H,Chung DJ,Koehne G,Jhanwar SC,Landgren O,Levine R,Giralt SA

更新日期：2017-08-01 00:00:00

abstract：:Whether long non-coding RNA (lncRNA) single-nucleotide polymorphisms (SNPs) affect prognosis of acute myeloid leukemia (AML) remains unknown. To search the association between lncRNA SNPs and AML outcomes, thirty tagSNPs in five lncRNAs were genotyped in 313 AML patients. Survival analysis indicated that GAS5 rs558296...

journal_title：Leukemia & lymphoma

authors： Yan H,Zhang DY,Li X,Yuan XQ,Yang YL,Zhu KW,Zeng H,Li XL,Cao S,Zhou HH,Zhang W,Chen XP

更新日期：2017-08-01 00:00:00

abstract：:We report the clinical features and outcome of 22 TLS-ERG+ leukemia patients (20 AML and 2 B-ALL). TLS-ERG was tightly associated with extramedullary disease (EMD), complex chromosome abnormalities, and high risk gene mutations including IKZF1, WT1, TET2, NOTCH2, and PHF6. The 6-month leukemia free survival (LFS) with...

journal_title：Leukemia & lymphoma

authors： Pan J,Zhang Y,Zhao YL,Yang JF,Zhang JP,Liu HX,Wu T,Tong CR

更新日期：2017-07-01 00:00:00

abstract：:In myelodysplastic syndrome (MDS), vascular endothelial growth factor (VEGF) may have regulatory effects on the hematopoietic system and contribute to disease progression. We analyzed by immunocytochemistry VEGF expression in bone marrow (BM) cells from 188 patients with MDS and 96 non-hemopathic subjects. We also mea...

journal_title：Leukemia & lymphoma

authors： Invernizzi R,Travaglino E,Della Porta MG,Malcovati L,Gallì A,Bastia R,Ciola M,Ambaglio I,Boveri E,Rosti V,Cazzola M

更新日期：2017-07-01 00:00:00

abstract：:Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated chronic lymphocytic leukemia (CLL) patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%)...

journal_title：Leukemia & lymphoma

authors： Finnes HD,Chaffee KG,Call TG,Ding W,Kenderian SS,Bowen DA,Conte M,McCullough KB,Merten JA,Bartoo GT,Smith MD,Leis J,Chanan-Khan A,Schwager SM,Slager SL,Kay NE,Shanafelt TD,Parikh SA

更新日期：2017-06-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that a...

journal_title：Leukemia & lymphoma

authors： Piggin A,Bayly E,Tam CS

更新日期：2017-06-01 00:00:00

abstract：:The term high-risk multiple myeloma is aimed to identify a heterogeneous group of patients who are more likely to progress and die early of their disease. Therefore, recognition of these patients is crucial. With the increase in the number of treatment options, the outcome for high-risk patients has probably improved,...

journal_title：Leukemia & lymphoma

authors： Muchtar E,Magen H,Gertz MA

更新日期：2017-06-01 00:00:00

abstract：:Relative risks of treatment-emergent adverse events (TEAEs) and related hospitalization is most accurate when accounting for treatment exposure. AZA-AML-001 showed azacitidine (AZA) prolonged overall survival versus conventional care regimens (CCR) in older patients (≥65 years) with acute myeloid leukemia (AML) by 3.9...

journal_title：Leukemia & lymphoma

authors： Seymour JF,Döhner H,Minden MD,Stone R,Gambini D,Dougherty D,Beach CL,Weaver J,Dombret H

更新日期：2017-06-01 00:00:00

abstract：:Treatment of diffuse large B-cell lymphoma (DLBCL) with R-CHOP(-like) regimens include large cumulative doses of prednisolone. In this retrospective study, we evaluated changes in vertebral bone density (VD) in DLBCL patients by measuring CT-ascertained Hounsfield units (HU) at the L3 level. In total, 111 patients dia...

journal_title：Leukemia & lymphoma

authors： Svendsen P,Shekhrajka N,Nielsen KL,Vestergaard P,Poulsen MØ,Vistisen AK,Munksgaard PS,Severinsen MT,Jensen P,Johnsen HE,Jakobsen LH,Bøgsted M,Frøkjær JB,El-Galaly TC

更新日期：2017-05-01 00:00:00

abstract：:Imatinib, which has revolutionized chronic myeloid leukemia (CML) treatment, was suggested to improve lipid profile. Statins, a dyslipidemia drug, were reported to potentiate imatinib's antileukemic effect. However, analysis of imatinib combined with statins is lacking. We have retrospectively analyzed the normalizati...

journal_title：Leukemia & lymphoma

authors： Ellis M,Krashin E,Hamburger-Avnery O,Gan S,Elis A,Ashur-Fabian O

更新日期：2017-05-01 00:00:00

abstract：:Anthracycline uptake could be affected by efflux pumps of the ABC family. The influence of 7 SNPs of ABC genes was evaluated in 225 adult de novo acute myeloid leukemia (AML) patients. After multivariate logistic regression there were no significant differences in complete remission, though induction death was associa...

journal_title：Leukemia & lymphoma

authors： Megías-Vericat JE,Montesinos P,Herrero MJ,Moscardó F,Bosó V,Rojas L,Martínez-Cuadrón D,Hervás D,Boluda B,García-Robles A,Rodríguez-Veiga R,Martín-Cerezuela M,Cervera J,Sendra L,Sanz J,Miguel A,Lorenzo I,Poveda JL,Sanz

更新日期：2017-05-01 00:00:00